FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy

Print Friendly, PDF & Email

PHASE 3 CLINICAL TRIAL FOR DUCHENNE MUSCULR DYSTROPHY: SAN FRANCISCO, Aug. 11, 2020 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) announced the initiation of LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab or placebo in combination with systemic corticosteroids in patients with non-ambulatory Duchenne muscular dystrophy (DMD). The primary objective of this global study is […]